Drug Approval | May 29, 2025
Zydus receives USFDA ‘Fast Track Designation’ for novel oral inhibitor ‘Usnoflast’
Usnoflast has previously also received ‘Orphan Drug Designation (ODD)’ from the USFDA
Usnoflast has previously also received ‘Orphan Drug Designation (ODD)’ from the USFDA
Orion will be the exclusive partner for the distribution, marketing, and sales of Shilpa's Recombinant Human Albumin in Europe
Merck KGaA, Darmstadt, Germany announced the presentation of new oncology data across more than 12 tumor types at ASCO 2025
3SBio will receive an upfront payment of $1.25 billion and is eligible to receive milestone payments associated with certain development, regulatory and commercial milestones up to $4.8 billion
Integrated facility to deliver end-to-end, customized workflows across life sciences, diagnostics, and applied markets
Syngene reported revenue growth of 11% year-on-year, and 8% sequentially crossing the Rs. 1,000 Cr in a quarter threshold for the first time
The capital raise will also support debt repayment or prepayment, improving the company's debt-to-equity ratio and overall financial resilience
The transaction is expected to be completed by May 15, 2025 or such other date as may be mutually agreed
The Simplera Sync is a disposable, all-in-one sensor that requires no fingersticks with SmartGuard
Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities
Subscribe To Our Newsletter & Stay Updated
